- Home
- FISI vs RNAC Comparison
FISI vs RNAC Comparison
Compare FISI & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- RNAC
- Stock Information
- Founded
- FISI 1817
- RNAC 2007
- Country
- FISI United States
- RNAC United States
- Employees
- FISI N/A
- RNAC N/A
- Industry
- FISI Major Banks
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- FISI Finance
- RNAC Health Care
- Exchange
- FISI Nasdaq
- RNAC Nasdaq
- Market Cap
- FISI 416.6M
- RNAC 422.4M
- IPO Year
- FISI 1999
- RNAC 2016
- Fundamental
- Price
- FISI $27.12
- RNAC $19.02
- Analyst Decision
- FISI Hold
- RNAC Strong Buy
- Analyst Count
- FISI 3
- RNAC 8
- Target Price
- FISI $26.67
- RNAC $41.67
- AVG Volume (30 Days)
- FISI 149.4K
- RNAC 161.9K
- Earning Date
- FISI 01-23-2025
- RNAC 11-07-2024
- Dividend Yield
- FISI 4.42%
- RNAC N/A
- EPS Growth
- FISI N/A
- RNAC N/A
- EPS
- FISI 3.17
- RNAC N/A
- Revenue
- FISI $216,605,000.00
- RNAC $47,938,000.00
- Revenue This Year
- FISI N/A
- RNAC $56.06
- Revenue Next Year
- FISI $6.00
- RNAC N/A
- P/E Ratio
- FISI $8.55
- RNAC N/A
- Revenue Growth
- FISI 9.25
- RNAC N/A
- 52 Week Low
- FISI $16.29
- RNAC $11.67
- 52 Week High
- FISI $29.34
- RNAC $41.87
- Technical
- Relative Strength Index (RSI)
- FISI 49.81
- RNAC 47.25
- Support Level
- FISI $26.62
- RNAC $16.70
- Resistance Level
- FISI $29.34
- RNAC $19.98
- Average True Range (ATR)
- FISI 0.94
- RNAC 2.39
- MACD
- FISI -0.10
- RNAC -0.37
- Stochastic Oscillator
- FISI 29.30
- RNAC 23.67
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.